Obesity and mediators of inflammation have been identified as the most important risk and predictive factors in postmenopausal breast cancer (BC) survivors using aromatase inhibitors (AIs). The gene discussed is CYP19A1; the disease is obesity due to melanocortin 4 receptor deficiency.